{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T18:06:20Z","timestamp":1790445980611,"version":"4.1.0"},"reference-count":55,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2021,4,28]],"date-time":"2021-04-28T00:00:00Z","timestamp":1619568000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,4,28]],"date-time":"2021-04-28T00:00:00Z","timestamp":1619568000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100000027","name":"National Institute on Alcohol Abuse and Alcoholism","doi-asserted-by":"publisher","award":["AA022977"],"award-info":[{"award-number":["AA022977"]}],"id":[{"id":"10.13039\/100000027","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000027","name":"National Institute on Alcohol Abuse and Alcoholism","doi-asserted-by":"publisher","award":["AA006420"],"award-info":[{"award-number":["AA006420"]}],"id":[{"id":"10.13039\/100000027","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["1F31DA047113-01"],"award-info":[{"award-number":["1F31DA047113-01"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005188","name":"Tobacco-Related Disease Research Program","doi-asserted-by":"publisher","award":["27IR-0047"],"award-info":[{"award-number":["27IR-0047"]}],"id":[{"id":"10.13039\/100005188","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005188","name":"Tobacco-Related Disease Research Program","doi-asserted-by":"publisher","award":["T31KT1859"],"award-info":[{"award-number":["T31KT1859"]}],"id":[{"id":"10.13039\/100005188","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Psychopharmacology"],"published-print":{"date-parts":[[2021,8]]},"DOI":"10.1007\/s00213-021-05845-4","type":"journal-article","created":{"date-parts":[[2021,4,28]],"date-time":"2021-04-28T09:03:39Z","timestamp":1619600619000},"page":"2201-2211","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":31,"title":["Cannabidiol reduces withdrawal symptoms in nicotine-dependent rats"],"prefix":"10.1007","volume":"238","author":[{"given":"Lauren C.","family":"Smith","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lani","family":"Tieu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raymond T.","family":"Suhandynata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brent","family":"Boomhower","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa","family":"Hoffman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yadira","family":"Sepulveda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lieselot L. G.","family":"Carrette","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeremiah D.","family":"Momper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert L.","family":"Fitzgerald","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kate","family":"Hanham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Dowling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8688-709X","authenticated-orcid":false,"given":"Marsida","family":"Kallupi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"George","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,4,28]]},"reference":[{"key":"5845_CR1","unstructured":"(2018) Cannabidiol (Epidiolex) for epilepsy. Med Lett Drugs Ther 60(1559): 182\u2013184"},{"issue":"6","key":"5845_CR2","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1203\/PDR.0b013e318186e5dd","volume":"64","author":"FJ Alvarez","year":"2008","unstructured":"Alvarez FJ, Lafuente H, Rey-Santano MC, Mielgo VE, Gastiasoro E, Rueda M, Pertwee RG, Castillo AI, Romero J, Martinez-Orgado J (2008) Neuroprotective effects of the nonpsychoactive cannabinoid cannabidiol in hypoxic-ischemic newborn piglets. Pediatr Res 64(6):653\u2013658","journal-title":"Pediatr Res"},{"issue":"11","key":"5845_CR3","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1007\/s40262-016-0400-9","volume":"55","author":"GD Anderson","year":"2016","unstructured":"Anderson GD, Chan LN (2016) Pharmacokinetic drug interactions with tobacco, cannabinoids and smoking cessation products. Clin Pharmacokinet 55(11):1353\u20131368","journal-title":"Clin Pharmacokinet"},{"key":"5845_CR4","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.neuropharm.2018.05.025","volume":"138","author":"D Bagdas","year":"2018","unstructured":"Bagdas D, Alkhlaif Y, Jackson A, Carroll FI, Ditre JW, Damaj MI (2018) New insights on the effects of varenicline on nicotine reward, withdrawal and hyperalgesia in mice. Neuropharmacology 138:72\u201379","journal-title":"Neuropharmacology"},{"issue":"1","key":"5845_CR5","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1007\/s002130100770","volume":"157","author":"E Carstens","year":"2001","unstructured":"Carstens E, Anderson KA, Simons CT, Carstens MI, Jinks SL (2001) Analgesia induced by chronic nicotine infusion in rats: differences by gender and pain test. Psychopharmacology 157(1):40\u201345","journal-title":"Psychopharmacology"},{"issue":"1","key":"5845_CR6","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/0165-0270(94)90144-9","volume":"53","author":"SR Chaplan","year":"1994","unstructured":"Chaplan SR, Bach FW, Pogrel JW, Chung JM, Yaksh TL (1994) Quantitative assessment of tactile allodynia in the rat paw. J Neurosci Methods 53(1):55\u201363","journal-title":"J Neurosci Methods"},{"issue":"11","key":"5845_CR7","doi-asserted-by":"publisher","first-page":"e28142","DOI":"10.1371\/journal.pone.0028142","volume":"6","author":"A Cippitelli","year":"2011","unstructured":"Cippitelli A, Astarita G, Duranti A, Caprioli G, Ubaldi M, Stopponi S, Kallupi M, Sagratini G, Rodriguez de Fonseca F, Piomelli D, Ciccocioppo R (2011) Endocannabinoid regulation of acute and protracted nicotine withdrawal: effect of FAAH inhibition. PLoS One 6(11):e28142","journal-title":"PLoS One"},{"issue":"4","key":"5845_CR8","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1016\/S0272-5231(21)00818-2","volume":"12","author":"C Cohen","year":"1991","unstructured":"Cohen C, Pickworth WB, Henningfield JE (1991) Cigarette smoking and addiction. Clin Chest Med 12(4):701\u2013710","journal-title":"Clin Chest Med"},{"issue":"1","key":"5845_CR9","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1111\/adb.12077","volume":"20","author":"A Cohen","year":"2015","unstructured":"Cohen A, Treweek J, Edwards S, Leao RM, Schulteis G, Koob GF, George O (2015) Extended access to nicotine leads to a CRF1 receptor dependent increase in anxiety-like behavior and hyperalgesia in rats. Addict Biol 20(1):56\u201368","journal-title":"Addict Biol"},{"issue":"3","key":"5845_CR10","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1007\/s00213-003-1445-7","volume":"168","author":"JF Cryan","year":"2003","unstructured":"Cryan JF, Bruijnzeel AW, Skjei KL, Markou A (2003) Bupropion enhances brain reward function and reverses the affective and somatic aspects of nicotine withdrawal in the rat. Psychopharmacology 168(3):347\u2013358","journal-title":"Psychopharmacology"},{"issue":"2","key":"5845_CR11","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1124\/jpet.103.054908","volume":"307","author":"MI Damaj","year":"2003","unstructured":"Damaj MI, Kao W, Martin BR (2003) Characterization of spontaneous and precipitated nicotine withdrawal in the mouse. J Pharmacol Exp Ther 307(2):526\u2013534","journal-title":"J Pharmacol Exp Ther"},{"issue":"3","key":"5845_CR12","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1124\/jpet.110.166850","volume":"334","author":"MI Damaj","year":"2010","unstructured":"Damaj MI, Grabus SD, Navarro HA, Vann RE, Warner JA, King LS, Wiley JL, Blough BE, Lukas RJ, Carroll FI (2010) Effects of hydroxymetabolites of bupropion on nicotine dependence behavior in mice. J Pharmacol Exp Ther 334(3):1087\u20131095","journal-title":"J Pharmacol Exp Ther"},{"issue":"6","key":"5845_CR13","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1111\/epi.12631","volume":"55","author":"O Devinsky","year":"2014","unstructured":"Devinsky O, Cilio MR, Cross H, Fernandez-Ruiz J, French J, Hill C, Katz R, Di Marzo V, Jutras-Aswad D, Notcutt WG, Martinez-Orgado J, Robson PJ, Rohrback BG, Thiele E, Whalley B, Friedman D (2014) Cannabidiol: pharmacology and potential therapeutic role in epilepsy and other neuropsychiatric disorders. Epilepsia 55(6):791\u2013802","journal-title":"Epilepsia"},{"issue":"2","key":"5845_CR14","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1016\/j.pbb.2005.01.028","volume":"81","author":"S Gonzalez","year":"2005","unstructured":"Gonzalez S, Cebeira M, Fernandez-Ruiz J (2005) Cannabinoid tolerance and dependence: a review of studies in laboratory animals. Pharmacol Biochem Behav 81(2):300\u2013318","journal-title":"Pharmacol Biochem Behav"},{"issue":"10","key":"5845_CR15","doi-asserted-by":"publisher","first-page":"2036","DOI":"10.1038\/s41386-018-0050-8","volume":"43","author":"G Gonzalez-Cuevas","year":"2018","unstructured":"Gonzalez-Cuevas G, Martin-Fardon R, Kerr TM, Stouffer DG, Parsons LH, Hammell DC, Banks SL, Stinchcomb AL, Weiss F (2018) Unique treatment potential of cannabidiol for the prevention of relapse to drug use: preclinical proof of principle. Neuropsychopharmacology 43(10):2036\u20132045","journal-title":"Neuropsychopharmacology"},{"issue":"4","key":"5845_CR16","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1016\/S0009-9236(97)90124-7","volume":"62","author":"SG Gourlay","year":"1997","unstructured":"Gourlay SG, Benowitz NL (1997) Arteriovenous differences in plasma concentration of nicotine and catecholamines and related cardiovascular effects after smoking, nicotine nasal spray, and intravenous nicotine. Clin Pharmacol Ther 62(4):453\u2013463","journal-title":"Clin Pharmacol Ther"},{"issue":"7","key":"5845_CR17","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1093\/ntr\/ntx183","volume":"20","author":"AK Hamouda","year":"2018","unstructured":"Hamouda AK, Jackson A, Bagdas D, Imad Damaj M (2018) Reversal of nicotine withdrawal signs through positive allosteric modulation of alpha4beta2 nicotinic acetylcholine receptors in male mice. Nicotine Tob Res 20(7):903\u2013907","journal-title":"Nicotine Tob Res"},{"issue":"5","key":"5845_CR18","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1037\/pha0000140","volume":"25","author":"M Hiler","year":"2017","unstructured":"Hiler M, Breland A, Spindle T, Maloney S, Lipato T, Karaoghlanian N, Shihadeh A, Lopez A, Ramoa C, Eissenberg T (2017) Electronic cigarette user plasma nicotine concentration, puff topography, heart rate, and subjective effects: influence of liquid nicotine concentration and user experience. Exp Clin Psychopharmacol 25(5):380\u2013392","journal-title":"Exp Clin Psychopharmacol"},{"issue":"1","key":"5845_CR19","doi-asserted-by":"publisher","first-page":"7568","DOI":"10.1038\/s41598-018-25846-2","volume":"8","author":"C Hindocha","year":"2018","unstructured":"Hindocha C, Freeman TP, Grabski M, Crudgington H, Davies AC, Stroud JB, Das RK, Lawn W, Morgan CJA, Curran HV (2018a) The effects of cannabidiol on impulsivity and memory during abstinence in cigarette dependent smokers. Sci Rep 8(1):7568","journal-title":"Sci Rep"},{"key":"5845_CR20","doi-asserted-by":"crossref","unstructured":"Hindocha C, Freeman TP, Grabski M, Stroud JB, Crudgington H, Davies AC, Das RK, Lawn W, Morgan, CJA, Curran HV (2018b) Cannabidiol reverses attentional bias to cigarette cues in a human experimental model of tobacco withdrawal. Addiction\u00a0113(9):1696\u20131705","DOI":"10.1111\/add.14243"},{"issue":"5","key":"5845_CR21","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1515\/cclm-2019-0600","volume":"58","author":"JA Hubbard","year":"2020","unstructured":"Hubbard JA, Smith BE, Sobolesky PM, Kim S, Hoffman MA, Stone J, Huestis MA, Grelotti DJ, Grant I, Marcotte TD, Fitzgerald RL (2020) Validation of a liquid chromatography tandem mass spectrometry (LC-MS\/MS) method to detect cannabinoids in whole blood and breath. Clin Chem Lab Med 58(5):673\u2013681","journal-title":"Clin Chem Lab Med"},{"issue":"2","key":"5845_CR22","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1038\/npp.2013.216","volume":"39","author":"M Igari","year":"2014","unstructured":"Igari M, Alexander JC, Ji Y, Qi X, Papke RL, Bruijnzeel AW (2014) Varenicline and cytisine diminish the dysphoric-like state associated with spontaneous nicotine withdrawal in rats. Neuropsychopharmacology 39(2):455\u2013465","journal-title":"Neuropsychopharmacology"},{"issue":"5","key":"5845_CR23","doi-asserted-by":"publisher","first-page":"1316","DOI":"10.1111\/adb.12423","volume":"22","author":"A Jackson","year":"2017","unstructured":"Jackson A, Silk S, Buhidma Y, Shoaib M (2017) Varenicline, the clinically effective smoking cessation agent, restores probabilistic response reversal performance during withdrawal from nicotine. Addict Biol 22(5):1316\u20131328","journal-title":"Addict Biol"},{"issue":"5","key":"5845_CR24","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1007\/s00210-006-0033-x","volume":"372","author":"M Kathmann","year":"2006","unstructured":"Kathmann M, Flau K, Redmer A, Trankle C, Schlicker E (2006) Cannabidiol is an allosteric modulator at mu- and delta-opioid receptors. Naunyn Schmiedebergs Arch Pharmacol 372(5):354\u2013361","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"issue":"1","key":"5845_CR25","doi-asserted-by":"publisher","first-page":"291","DOI":"10.3906\/sag-1809-11","volume":"50","author":"SZ Khan","year":"2020","unstructured":"Khan SZ, Farooq A, Masood M, Shahid A, Khan IU, Nisar H, Fatima I (2020) Smokeless tobacco use and risk of oral cavity cancer. Turk J Med Sci 50(1):291\u2013297","journal-title":"Turk J Med Sci"},{"key":"5845_CR26","doi-asserted-by":"crossref","unstructured":"Kallupi M, Xue S, Zhou B, Janda KD, George O (2018) An enzymatic approach reverses nicotine dependence, decreases compulsive-like intake, and prevents relapse. Sci Adv 4(10):eeat4751\u00a0","DOI":"10.1126\/sciadv.aat4751"},{"key":"5845_CR27","doi-asserted-by":"crossref","unstructured":"Kallupi M, de Guglielmo G, Larrosa E, George O (2019) Exposure to passive nicotine vapor in male adolescent rats produces a withdrawal-like state and facilitates nicotine self-administration during adulthood. Eur Neuropsychopharmacology 29(11):1227\u20131234","DOI":"10.1016\/j.euroneuro.2019.08.299"},{"issue":"3","key":"5845_CR28","doi-asserted-by":"publisher","first-page":"129","DOI":"10.14740\/jocmr4090","volume":"12","author":"C Larsen","year":"2020","unstructured":"Larsen C, Shahinas J (2020) Dosage, efficacy and safety of cannabidiol administration in adults: a systematic review of human trials. J Clin Med Res 12(3):129\u2013141","journal-title":"J Clin Med Res"},{"issue":"5","key":"5845_CR29","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1111\/j.1360-0443.1991.tb01811.x","volume":"86","author":"SJ Leischow","year":"1991","unstructured":"Leischow SJ, Stitzer ML (1991) Smoking cessation and weight gain. Br J Addict 86(5):577\u2013581","journal-title":"Br J Addict"},{"key":"5845_CR30","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1016\/j.pbb.2013.08.013","volume":"111","author":"DJ Liput","year":"2013","unstructured":"Liput DJ, Hammell DC, Stinchcomb AL, Nixon K (2013) Transdermal delivery of cannabidiol attenuates binge alcohol-induced neurodegeneration in a rodent model of an alcohol use disorder. Pharmacol Biochem Behav 111:120\u2013127","journal-title":"Pharmacol Biochem Behav"},{"issue":"1\u20133","key":"5845_CR31","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1016\/j.ejphar.2013.10.011","volume":"720","author":"M Mahgoub","year":"2013","unstructured":"Mahgoub M, Keun-Hang SY, Sydorenko V, Ashoor A, Kabbani N, Al Kury L, Sadek B, Howarth CF, Isaev D, Galadari S, Oz M (2013) Effects of cannabidiol on the function of alpha7-nicotinic acetylcholine receptors. Eur J Pharmacol 720(1\u20133):310\u2013319","journal-title":"Eur J Pharmacol"},{"key":"5845_CR32","doi-asserted-by":"crossref","unstructured":"Malin DH, Goyarzu P (2009) Rodent models of nicotine withdrawal syndrome. Handb Exp Pharmacol (192): 401\u2013434","DOI":"10.1007\/978-3-540-69248-5_14"},{"issue":"3","key":"5845_CR33","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1016\/0091-3057(92)90408-8","volume":"43","author":"DH Malin","year":"1992","unstructured":"Malin DH, Lake JR, Newlin-Maultsby P, Roberts LK, Lanier JG, Carter VA, Cunningham JS, Wilson OB (1992) Rodent model of nicotine abstinence syndrome. Pharmacol Biochem Behav 43(3):779\u2013784","journal-title":"Pharmacol Biochem Behav"},{"issue":"3\u20134","key":"5845_CR34","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1007\/s00213-005-0135-z","volume":"184","author":"DH Malin","year":"2006","unstructured":"Malin DH, Lake JR, Smith TD, Khambati HN, Meyers-Paal RL, Montellano AL, Jennings RE, Erwin DS, Presley SE, Perales BA (2006) Bupropion attenuates nicotine abstinence syndrome in the rat. Psychopharmacology 184(3\u20134):494\u2013503","journal-title":"Psychopharmacology"},{"issue":"4","key":"5845_CR35","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1080\/14622200110073380","volume":"3","author":"A Markou","year":"2001","unstructured":"Markou A, Paterson NE (2001) The nicotinic antagonist methyllycaconitine has differential effects on nicotine self-administration and nicotine withdrawal in the rat. Nicotine Tob Res 3(4):361\u2013373","journal-title":"Nicotine Tob Res"},{"key":"5845_CR36","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1007\/978-3-319-13482-6_4","volume":"24","author":"I McLaughlin","year":"2015","unstructured":"McLaughlin I, Dani JA, De Biasi M (2015) Nicotine withdrawal. Curr Top Behav Neurosci 24:99\u2013123","journal-title":"Curr Top Behav Neurosci"},{"issue":"7","key":"5845_CR37","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1586\/14737175.6.7.965","volume":"6","author":"ME Mooney","year":"2006","unstructured":"Mooney ME, Sofuoglu M (2006) Bupropion for the treatment of nicotine withdrawal and craving. Expert Rev Neurother 6(7):965\u2013981","journal-title":"Expert Rev Neurother"},{"issue":"9","key":"5845_CR38","doi-asserted-by":"publisher","first-page":"2433","DOI":"10.1016\/j.addbeh.2013.03.011","volume":"38","author":"CJ Morgan","year":"2013","unstructured":"Morgan CJ, Das RK, Joye A, Curran HV, Kamboj SK (2013) Cannabidiol reduces cigarette consumption in tobacco smokers: preliminary findings. Addict Behav 38(9):2433\u20132436","journal-title":"Addict Behav"},{"issue":"1","key":"5845_CR39","doi-asserted-by":"publisher","first-page":"e53","DOI":"10.1002\/cpns.53","volume":"85","author":"AR Pahng","year":"2018","unstructured":"Pahng AR, Edwards S (2018) Measuring pain avoidance-like behavior in drug-dependent rats. Curr Protoc Neurosci 85(1):e53","journal-title":"Curr Protoc Neurosci"},{"issue":"5","key":"5845_CR40","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1037\/0022-006X.61.5.768","volume":"61","author":"KA Perkins","year":"1993","unstructured":"Perkins KA (1993) Weight gain following smoking cessation. J Consult Clin Psychol 61(5):768\u2013777","journal-title":"J Consult Clin Psychol"},{"key":"5845_CR41","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1146\/annurev-med-111314-033712","volume":"67","author":"JJ Prochaska","year":"2016","unstructured":"Prochaska JJ, Benowitz NL (2016) The past, present, and future of nicotine addiction therapy. Annu Rev Med 67:467\u2013486","journal-title":"Annu Rev Med"},{"issue":"6017","key":"5845_CR42","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1136\/bmj.1.6017.1043","volume":"1","author":"MA Russell","year":"1976","unstructured":"Russell MA, Feyerabend C, Cole PV (1976) Plasma nicotine levels after cigarette smoking and chewing nicotine gum. Br Med J 1(6017):1043\u20131046","journal-title":"Br Med J"},{"issue":"8","key":"5845_CR43","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1007\/s11064-005-6978-1","volume":"30","author":"EB Russo","year":"2005","unstructured":"Russo EB, Burnett A, Hall B, Parker KK (2005) Agonistic properties of cannabidiol at 5-HT1a receptors. Neurochem Res 30(8):1037\u20131043","journal-title":"Neurochem Res"},{"issue":"3","key":"5845_CR44","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1007\/s002130050954","volume":"143","author":"M Shoaib","year":"1999","unstructured":"Shoaib M, Stolerman IP (1999) Plasma nicotine and cotinine levels following intravenous nicotine self-administration in rats. Psychopharmacology 143(3):318\u2013321","journal-title":"Psychopharmacology"},{"key":"5845_CR45","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.neuropharm.2017.05.031","volume":"124","author":"ME Sloan","year":"2017","unstructured":"Sloan ME, Gowin JL, Ramchandani VA, Hurd YL, Le Foll B (2017) The endocannabinoid system as a target for addiction treatment: trials and tribulations. Neuropharmacology 124:73\u201383","journal-title":"Neuropharmacology"},{"key":"5845_CR46","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.cca.2019.01.002","volume":"491","author":"PM Sobolesky","year":"2019","unstructured":"Sobolesky PM, Smith BE, Hubbard JA, Stone J, Marcotte TD, Grelotti DJ, Grant I, Fitzgerald RL (2019) Validation of a liquid chromatography-tandem mass spectrometry method for analyzing cannabinoids in oral fluid. Clin Chim Acta 491:30\u201338","journal-title":"Clin Chim Acta"},{"key":"5845_CR47","first-page":"163","volume":"261","author":"ML Stitzer","year":"1988","unstructured":"Stitzer ML, Gross J (1988) Smoking relapse: the role of pharmacological and behavioral factors. Prog Clin Biol Res 261:163\u2013184","journal-title":"Prog Clin Biol Res"},{"issue":"1","key":"5845_CR48","doi-asserted-by":"publisher","first-page":"86","DOI":"10.3109\/03602532.2013.849268","volume":"46","author":"SM Stout","year":"2014","unstructured":"Stout SM, Cimino NM (2014) Exogenous cannabinoids as substrates, inhibitors, and inducers of human drug metabolizing enzymes: a systematic review. Drug Metab Rev 46(1):86\u201395","journal-title":"Drug Metab Rev"},{"issue":"5","key":"5845_CR49","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1038\/sj.bjp.0707133","volume":"150","author":"A Thomas","year":"2007","unstructured":"Thomas A, Baillie GL, Phillips AM, Razdan RK, Ross RA, Pertwee RG (2007) Cannabidiol displays unexpectedly high potency as an antagonist of CB1 and CB2 receptor agonists in vitro. Br J Pharmacol 150(5):613\u2013623","journal-title":"Br J Pharmacol"},{"issue":"1","key":"5845_CR50","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1111\/adb.12495","volume":"23","author":"A Viudez-Martinez","year":"2018","unstructured":"Viudez-Martinez A, Garcia-Gutierrez MS, Navarron CM, Morales-Calero MI, Navarrete F, Torres-Suarez AI, Manzanares J (2018) Cannabidiol reduces ethanol consumption, motivation and relapse in mice. Addict Biol 23(1):154\u2013164","journal-title":"Addict Biol"},{"issue":"3","key":"5845_CR51","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1038\/s41401-018-0032-8","volume":"40","author":"A Viudez-Martinez","year":"2019","unstructured":"Viudez-Martinez A, Garcia-Gutierrez MS, Medrano-Relinque J, Navarron CM, Navarrete F, Manzanares J (2019) Cannabidiol does not display drug abuse potential in mice behavior. Acta Pharmacol Sin 40(3):358\u2013364","journal-title":"Acta Pharmacol Sin"},{"issue":"13","key":"5845_CR52","doi-asserted-by":"publisher","first-page":"1914","DOI":"10.1002\/cncr.28695","volume":"120","author":"GW Warren","year":"2014","unstructured":"Warren GW, Alberg AJ, Kraft AS, Cummings KM (2014) The 2014 Surgeon General\u2019s report: \u201cThe health consequences of smoking\u201350 years of progress\u201d: a paradigm shift in cancer care. Cancer 120(13):1914\u20131916","journal-title":"Cancer"},{"issue":"3","key":"5845_CR53","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1007\/s00213-007-1041-3","volume":"197","author":"R West","year":"2008","unstructured":"West R, Baker CL, Cappelleri JC, Bushmakin AG (2008) Effect of varenicline and bupropion SR on craving, nicotine withdrawal symptoms, and rewarding effects of smoking during a quit attempt. Psychopharmacology 197(3):371\u2013377","journal-title":"Psychopharmacology"},{"issue":"14","key":"5845_CR54","doi-asserted-by":"publisher","first-page":"1686","DOI":"10.1039\/C7CC09134F","volume":"54","author":"S Xue","year":"2018","unstructured":"Xue S, Kallupi M, Zhou B, Smith LC, Miranda PO, George O, Janda KD (2018) An enzymatic advance in nicotine cessation therapy. Chem Commun (Camb) 54(14):1686\u20131689","journal-title":"Chem Commun (Camb)"},{"issue":"3","key":"5845_CR55","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1590\/S1516-44462008000300015","volume":"30","author":"AW Zuardi","year":"2008","unstructured":"Zuardi AW (2008) Cannabidiol: from an inactive cannabinoid to a drug with wide spectrum of action. Braz J Psychiatry 30(3):271\u2013280","journal-title":"Braz J Psychiatry"}],"container-title":["Psychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00213-021-05845-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00213-021-05845-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00213-021-05845-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,21]],"date-time":"2021-07-21T03:37:36Z","timestamp":1626838656000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00213-021-05845-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,28]]},"references-count":55,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2021,8]]}},"alternative-id":["5845"],"URL":"https:\/\/doi.org\/10.1007\/s00213-021-05845-4","relation":{},"ISSN":["0033-3158","1432-2072"],"issn-type":[{"value":"0033-3158","type":"print"},{"value":"1432-2072","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,4,28]]},"assertion":[{"value":"3 September 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 April 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 April 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Joseph Dowling and Kate Hanham are CEO and Acting Sr. VP of Development of CV Sciences, Inc.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}